Compare Stocks: PRTA, ALVO, VIR, and NVAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$6.11 +12.1%	$4.78	$2.94 ▼ $9.05	$1.84B	0.2	750,913 shs	2.90 million shs
NVAX Novavax	$12.56 +20.1%	$9.15	$6.20 ▼ $13.39	$2.07B	2.44	4.91 million shs	28.45 million shs
PRTA Prothena	$8.27 -1.1%	$8.90	$7.73 ▼ $11.80	$432.93M	-0.29	508,302 shs	714,460 shs
VIR Vir Biotechnology	$11.78 +5.5%	$10.19	$4.82 ▼ $11.94	$1.99B	1.59	2.43 million shs	3.13 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-5.22%	+2.44%	+57.51%	-34.50%
NVAX Novavax	0.00%	-1.60%	+2.35%	+11.87%	+10.57%
PRTA Prothena	0.00%	+0.84%	-14.87%	-12.00%	-15.73%
VIR Vir Biotechnology	0.00%	+4.78%	-1.93%	+11.48%	+94.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$6.11 +12.1%	$4.78	$2.94 ▼ $9.05	$1.84B	0.2	750,913 shs	2.90 million shs
NVAX Novavax	$12.56 +20.1%	$9.15	$6.20 ▼ $13.39	$2.07B	2.44	4.91 million shs	28.45 million shs
PRTA Prothena	$8.27 -1.1%	$8.90	$7.73 ▼ $11.80	$432.93M	-0.29	508,302 shs	714,460 shs
VIR Vir Biotechnology	$11.78 +5.5%	$10.19	$4.82 ▼ $11.94	$1.99B	1.59	2.43 million shs	3.13 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-5.22%	+2.44%	+57.51%	-34.50%
NVAX Novavax	0.00%	-1.60%	+2.35%	+11.87%	+10.57%
PRTA Prothena	0.00%	+0.84%	-14.87%	-12.00%	-15.73%
VIR Vir Biotechnology	0.00%	+4.78%	-1.93%	+11.48%	+94.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$8.50	39.00% Upside
NVAX Novavax	2.33	Hold	$14.00	11.69% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	199.10% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	85.85% Upside

Current Analyst Ratings Breakdown

Latest PRTA, ALVO, VIR, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/24/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/17/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
9/16/2026	ALVO Alvotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Overweight	$4.00 ➝ $8.00
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/31/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$588.90M	3.13	$0.24 per share	25.01	($0.94) per share	-6.51
NVAX Novavax	$1.12B	1.84	$4.21 per share	2.98	($0.79) per share	-15.87
PRTA Prothena	$9.68M	44.43	N/A	N/A	$5.21 per share	1.58
VIR Vir Biotechnology	$68.56M	28.65	N/A	N/A	$5.50 per share	2.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	25.48	N/A	-36.31%	N/A	-11.73%	11/11/2026 (Estimated)
NVAX Novavax	$440.30M	-$1.52	N/A	N/A	N/A	-59.87%	-14.82%	-13.35%	11/5/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	2.95	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	N/A	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest PRTA, ALVO, VIR, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.2230	$103.00 million	$106.00 million
8/6/2026	Q2 2026	NVAX Novavax	-$0.3798	-$0.32	+$0.0598	-$0.32	$52.51 million	$56.70 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
NVAX Novavax	N/A	2.33	2.30
PRTA Prothena	N/A	25.05	25.05
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
NVAX Novavax	53.04%
PRTA Prothena	97.08%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	N/A
NVAX Novavax	1.60%
PRTA Prothena	10.40%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
NVAX Novavax	749	164.95 million	162.31 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable

PRTA, ALVO, VIR, and NVAX Headlines

Recent News About These Companies

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

55 minutes ago | businesswire.com

Vir Biotechnology Names Aziz Sawaf as CFO

October 1, 2026 | marketscreener.comM

Vir Biotechnology Names Aziz Sawaf Chief Financial Officer

October 1, 2026 | marketwatch.com

Vir Biotechnology, Inc. Announces Executive Changes

October 1, 2026 | marketscreener.comM

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

October 1, 2026 | biospace.comB

Vir Biotechnology Appoints Aziz Sawaf As CFO

October 1, 2026 | pulse2.comP

Raymond James reiterates USD 19.00 target for Vir Biotechnology stock

October 1, 2026 | ad-hoc-news.deA

Vir Biotechnology, Inc. (VIR) Stock Earnings Call Transcripts - Yahoo Finance

September 30, 2026 | finance.yahoo.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 30, 2026 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

September 30, 2026 | marketbeat.com

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

September 29, 2026 | seekingalpha.com

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir

September 28, 2026 | fiercebiotech.comF

GeoVax Labs (NASDAQ:GOVX) & Vir Biotechnology (NASDAQ:VIR) Head to Head Contrast

September 27, 2026 | americanbankingnews.com

Can Vir Biotechnology (NASDAQ:VIR) deliver on its packed clinical calendar?

September 26, 2026 | kalkinemedia.comK

Bank of America Corp DE Acquires 1,142,539 Shares of Vir Biotechnology, Inc. $VIR

September 26, 2026 | marketbeat.com

Vir Biotechnology stock falls 3.34 percent after Q2 results

September 25, 2026 | ad-hoc-news.deA

Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR

September 18, 2026 | marketbeat.com

Vir Biotechnology, Inc. $VIR Shares Acquired by Squarepoint Ops LLC

September 17, 2026 | marketbeat.com

WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR

September 13, 2026 | marketbeat.com

Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR

September 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRTA, ALVO, VIR, and NVAX Company Descriptions

Alvotech NASDAQ:ALVO

$6.11 +0.66 (+12.11%)

Closing price 04:00 PM Eastern

Extended Trading

$6.06 -0.05 (-0.82%)

As of 04:55 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Novavax NASDAQ:NVAX

$12.56 +2.10 (+20.08%)

Closing price 04:00 PM Eastern

Extended Trading

$12.54 -0.02 (-0.19%)

As of 05:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Prothena NASDAQ:PRTA

$8.27 -0.09 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$8.28 +0.01 (+0.12%)

As of 04:15 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Vir Biotechnology NASDAQ:VIR

$11.78 +0.61 (+5.46%)

Closing price 04:00 PM Eastern

Extended Trading

$11.71 -0.07 (-0.56%)

As of 04:44 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, ALVO, VIR, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, ALVO, VIR, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, ALVO, VIR, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, ALVO, VIR, and NVAX Company Descriptions

Alvotech NASDAQ:ALVO

Novavax NASDAQ:NVAX

Prothena NASDAQ:PRTA

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, ALVO, VIR, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, ALVO, VIR, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, ALVO, VIR, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, ALVO, VIR, and NVAX Company Descriptions

Alvotech NASDAQ:ALVO

Novavax NASDAQ:NVAX

Prothena NASDAQ:PRTA

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools